{
    "nct_id": "NCT02899052",
    "official_title": "A Phase 2, Open-Label, Multi-Center Study of Venetoclax in Combination With Carfilzomib and Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma",
    "inclusion_criteria": "* Eastern Collaborative Oncology Group (ECOG) performance score of less than or equal to 2.\n* Documented relapsed or progressive Multiple Myeloma (MM) on or after any regimen or is refractory to the most recent line of therapy.\n* Positive for translocation t(11;14) as determined by an analytically validated Fluorescent In Situ Hybridization (FISH) assay per central laboratory testing.\n* Received prior treatment with at least 1 prior line of therapy for MM.\n* Measurable disease on Screening per International Myeloma Working Group (IMWG) criteria.\n* Meets absolute neutrophil count, platelet count, hemoglobin, liver and kidney function laboratory values within 2 weeks prior to first dose of study drug.\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Has a pre-existing condition that is contraindicated including.\n\n  * Non-secretory or oligo-secretory MM\n  * Active plasma cell leukemia.\n  * Waldenström's macroglobulinemia.\n  * Primary amyloidosis.\n  * POEMS syndrome (polyneuropathy, organomegaly, endocrinopathy, monoclonal protein, and skin changes).\n  * Active hepatitis B or C infection based on screening blood testing.\n  * Known active Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection.\n  * Significant cardiovascular disease.\n  * Major surgery within 4 weeks prior to first dose.\n  * Acute infections requiring antibiotic, antifungal or antiviral therapy within14 days prior to first dose.\n  * Peripheral neuropathy ≥ Grade 3 or ≥ Grade 2 with pain within 2 weeks prior to first dose.\n  * Uncontrolled diabetes or uncontrolled hypertension within 14 days prior to first dose.\n  * Any other medical condition that, in the opinion of the Investigator, would adversely affect the participant's participation in the study.\n* History of other active malignancies, including myelodysplastic syndrome (MDS), within the past 3 years prior to study entry Other protocol defined inclusion/exclusion criteria could apply",
    "miscellaneous_criteria": ""
}